Abstract

BackgroundThe treatment of advanced cancer often involves potentially life-shortening end-of-life decisions (ELDs). This study aimed to examine the prevalence and characteristics of ELDs in different cancer types.MethodsA nationwide death certificate study was conducted based on a large random sample of all deaths in Flanders, Belgium, between 1 January and 30 June 2013. All cancer deaths were selected (n = 2392). Attending physicians were sent a questionnaire about ELDs and the preceding decision-making process.ResultsThe response rate was 58.3%. Across cancer types, a non-treatment decision occurred in 7.6–14.0%, intensified pain and symptom alleviation in 37.5–41.7%, euthanasia or physician-assisted suicide in 8.7–12.6%, and life shortening without explicit patient request in 1.0–2.4%. ELD prevalence did not differ significantly by cancer type. Reasons for ELDs were most frequently patient’s physical suffering and lack of prospect of improvement. ‘Anticipated further suffering’ and ‘unbearable situation for relatives’ were reasons more often reported in haematological cancer than in other cancer types. Patient, family, and caregiver involvement in decision-making did not differ across cancer types.ConclusionsEuthanasia or physician-assisted suicide rates were relatively high in all cancer types. Neither the prevalence of ELDs nor characteristics of the decision-making process differed substantially between cancer types. This indicates a uniform approach to end-of-life care, including palliative care, across oncological settings.

Highlights

  • Many people with advanced cancer face difficult treatment decisions at the end of life

  • The aim of this study is to examine the prevalence of end-of-life decisions (ELDs) and the characteristics of the decision-making process in people dying from different cancer types in 2013 in Flanders, Belgium, a country where euthanasia has been legal under specific conditions since 2002

  • End-of-life decisions were found to be common in all cancer types, with high euthanasia or physicianassisted suicide rates (8.7–12.6% across cancer types)

Read more

Summary

Introduction

Many people with advanced cancer face difficult treatment decisions at the end of life In responding to these decisions, patients need to balance the realistic possibilities of prolonging life by continuing treatment or starting new treatments on the one hand, against comfort and quality of life on the other hand.[1] As a result, it can happen that decisions are made that may potentially hasten the patient’s death. Neither the prevalence of ELDs nor characteristics of the decision-making process differed substantially between cancer types This indicates a uniform approach to end-of-life care, including palliative care, across oncological settings

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call